Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study
PLOS Medicine · 2024
DOI: 10.1371/journal.pmed.1004479 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, 2024. Verfasst von Rongtao Lai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, United States of America. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Natural Science Foundation of China, Shanghai Municipal Key Clinical Specialty.
Abstract (Originalsprache)
Background Detailed subgroup incidence rates for steatotic liver disease (SLD)-related hepatocellular carcinoma (HCC) are critical to inform practice and public health interventions but remain sparse. We aimed to fill in this gap. Methods and findings In a retrospective cohort study of adults with SLD from the United States (US) Merative Marketscan Research Databases (1/2007 to 12/2021), we estimated HCC incidence stratified by sex, age, cirrhosis, diabetes mellitus (DM), and a combination of all these 4 factors. We excluded patients with significant alcohol use and chronic viral hepatitis. We analyzed data from 741,816 patients with SLD (mean age 51.5 ± 12.8 years, 46% male, 14.7% cirrhosis). During a 2,410,166 person-years (PY) follow-up, 1,740 patients developed HCC. The overall HCC incidence yielded 0.72 per 1,000 PY (95% confidence interval [CI, 0.68, 0.75]). The incidence was higher in males (0.95, 95% CI [0.89, 1.01]) compared to females (0.52, 95% CI [0.48, 0.56]) ( p < 0.001). For those with cirrhosis, the incidence was significantly higher at 4.29 (95% CI [4.06, 4.51]) compared to those without cirrhosis (0.14, 95% CI [0.13, 0.16]) ( p < 0.001). Additionally, the incidence was higher in patients with DM (1.19, 95% CI [1.12, 1.26]) compared to those without DM (0.41, 95% CI [0.38, 0.44]) ( p < 0.001). Chronic kidney disease (CKD) was also associated with a higher HCC incidence of 2.20 (95% CI [2.00, 2.41]) compared to those without CKD (0.58, 95% CI [0.55, 0.62]) ( p < 0.001). Similarly, individuals with cardiovascular disease (CVD) had a higher HCC incidence of 1.89 (95% CI [1.75, 2.03]) compared to those without CVD (0.51, 95% CI [0.48, 0.54]) ( p < 0.001). Finally, the incidence of HCC was significantly higher in patients with non-liver cancer (3.90, 95% CI [3.67, 4.12]) compared to those without other cancers (0.29, 95% CI [0.26, 0.31]) ( p < 0.001). On further stratification, HCC incidence incrementally rose by 10-year age intervals, male sex, cirrhosis, and DM, reaching 19.06 (95% CI [16.10, 22.01]) and 8.44 (95% CI [6.78, 10.10]) in males and females, respectively, but only 0.04 for non-diabetic, noncirrhotic aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, United States of America.
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Division of Gastroenterology and Hepatology, Palo Alto Veterans Affairs Medical Center, Palo Alto, California, United States of America.
- Department of Epidemiology and Population Health, Stanford University, Palo Alto, California, United States of America.
ORCID-Profile: Rongtao Lai, Mindie H Nguyen
Förderung
- NCATS NIH HHS
- National Natural Science Foundation of China
- Shanghai Municipal Key Clinical Specialty
- Shanghai Municipal Planning Commission of Science and Research Fund
Zitieren
APA
Lai, R., Barnett, S., Zhang, X., Kam, L. Y., Cheung, R., Xie, Q., & Nguyen, M. H. (2024). Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004479
Vancouver
Lai R, Barnett S, Zhang X, Kam LY, Cheung R, Xie Q, et al. Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004479
BibTeX
@article{Lai2024,
author = {Lai, Rongtao and Barnett, Scott and Zhang, Xinrong and Kam, Leslie Yeeman and Cheung, Ramsey and Xie, Qing and Nguyen, Mindie H},
title = {Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study},
journal = {PLOS Medicine},
year = {2024},
doi = {10.1371/journal.pmed.1004479}
}
EUVIMED